Summary of Key Points from the Conference Call Company Overview - The company positions 2025 as a strategic turning point, aiming to drive profitability from commercialized products to ensure positive cash flow and develop new pipelines for the global market [2][3]. Core Products and Pipeline - The core tri-antibody drug (PD-1/CTLA-4/VEGF) achieves high efficacy with low toxicity through a monovalent binding model, enhancing immune activity by tens to thousands of times, with grade 3 or higher treatment-related adverse events (TRAE) at only 4.4% [2][4]. - The tri-antibody drug shows an objective response rate (ORR) in first-line non-small cell lung cancer (NSCLC) nearly double that of Keytruda, with ORR for later-line immune-oncology (IO) treated patients reaching 25%-31.3%, significantly outperforming existing dual-antibody therapies [2][5]. - The company plans to initiate Phase III clinical trials for the tri-antibody product by the end of 2026, targeting an overall survival (OS) hazard ratio (HR) of 0.65-0.7, with a peak commercial value target of $50 billion [2][7]. Clinical Development and Efficacy - The tri-antibody drug's Phase I clinical trial began on March 4, 2025, with initial data from 72 patients showing no dose-limiting toxicities and low rates of grade 3 or higher TRAE [5][6]. - The drug has demonstrated broad anti-tumor potential across various cancers, including triple-negative breast cancer, ovarian cancer, colorectal cancer, prostate cancer, and gastric cancer [6][12]. - In first-line NSCLC treatment, the tri-antibody drug's ORR is reported to be nearly double that of Keytruda, with ongoing studies to confirm its efficacy [10][11]. Market Positioning and Financial Outlook - The company aims to position the tri-antibody drug as a next-generation IO therapy, with a potential market size exceeding $30 billion, significantly higher than Keytruda's $30 billion peak value [7][13]. - The commercialized product, Pralsetinib, is expected to see a 5-8 times increase in sales after entering the national medical insurance directory in 2026, contributing to the company's goal of reaching a market capitalization of HKD 100 billion within five years [2][15]. Safety and Adverse Events - Safety data for the tri-antibody drug continues to show favorable outcomes, with low rates of VEGF-related toxicities, supporting its positioning as a backbone product for combination therapies [9][10]. Future Clinical Plans - The company plans to prioritize large indications for registration clinical trials, particularly in NSCLC, while also exploring cold tumors where IO therapies have been less effective [23][27]. - The upcoming ASCO conference will present larger sample data for the tri-antibody drug, with a focus on its efficacy in various subgroups [21][27]. ADC Development - The ROR1 ADC drug has shown an ORR of 95.5% in first-line treatment of DLBCL when combined with R-CHOP, with plans for further clinical exploration [14]. - The company’s ADC platform aims to enhance specificity and reduce systemic toxicity through innovative design strategies [17]. Financial Performance - In 2025, the company anticipates a revenue of CNY 269 million, with a focus on increasing cash reserves to support core product development and commercialization strategies [18][19]. Management and Shareholder Insights - The management expresses no intention to reduce their holdings, aiming for a market capitalization of HKD 100 billion within five years, with plans for potential stock repurchases during low price periods [20]. This summary encapsulates the key points discussed in the conference call, highlighting the company's strategic direction, product pipeline, clinical developments, market positioning, and financial outlook.

Group 1: Stock Market Movements - China Merchants Energy (01138) fell over 5%, currently down 4.09%, as the company assesses safety conditions regarding its vessels in the Strait of Hormuz [1] - Shenzhen Expressway (00548) dropped over 9%, currently down 7.86%, after reporting 2025 revenue of approximately 9.264 billion yuan, a 0.2% year-on-year increase, and a net profit of about 1.149 billion yuan, up 0.38% [1] - Television Broadcasts (00511) rose nearly 3% after announcing a 2025 revenue of 3.192 billion HKD, a 2.02% decrease, and a shareholder loss of 491 million HKD [2] - Chaoyun Group (06601) increased over 6%, currently up 4.07%, reporting a revenue of 1.988 billion yuan, a 9.24% year-on-year growth, and a net profit of 224 million yuan, up 9.98% [2] - Golden stocks fell again, with companies like Zijing Mining (02899) and Shandong Gold (01787) experiencing declines of 3.09% and 4.02% respectively, as spot gold prices dipped below 4500 USD [3] Group 2: Company Earnings and Forecasts - GSK Group (01285) surged over 40%, currently up 31.87%, after announcing an expected net profit of between 101.4 million and 111.1 million yuan for the year ending December 31, 2025, representing a year-on-year increase of approximately 210% to 230% [4] - Aoda Holdings (09929) fell over 12%, currently down 16.19%, reporting a revenue of 66.258 million HKD, a 27.75% decrease, and a net loss of 18.856 million HKD [5] - Peijia Medical (09996) rose nearly 4%, reporting a revenue of 713 million yuan, a 15.82% year-on-year increase, and a narrowed net loss [3] Group 3: Market Trends and Sector Performance - The pork concept stocks collectively declined, with COFCO Joycome (01610) down 3.57% as the average trading price of lean pigs fell below 10 yuan/kg, marking a 15-year low [3] - Semiconductor stocks saw a strong start, with Arm Holdings (ARM.US) rising 16.38% after announcing its entry into chip manufacturing, aiming for 15 billion USD in annual revenue within five years [8] - AI application software stocks collectively rose, with Braze (BRZE.US) increasing by 19.87% [8]

Core Viewpoint - 基石药业's stock price increased by over 8% at the close, currently up 6.73% at 6.66 HKD, with a trading volume of 93.12 million HKD, following the approval of a new indication for Shugli monoclonal antibody by the UK MHRA for treating specific adult patients with advanced non-small cell lung cancer (NSCLC) [1] Group 1 - 基石药业 announced that the new indication for Shugli monoclonal antibody has been approved for use in adult patients with advanced NSCLC who have PD-L1 expression ≥1%, no EGFR sensitive mutations or ALK/ROS1 genomic alterations, and have not shown disease progression after platinum-based chemoradiotherapy [1] - 平安证券's research report highlights that 基石药业 is leveraging clinical development as a growth engine, with reliable cash flow from commercialized products in the R&D 1.0 phase and innovative project layouts in the R&D 2.0 phase [1] - The core products of 基石药业 have entered clinical trial stages, with plans to continue advancing candidate projects into clinical trials, projecting revenues of 195 million, 464 million, and 633 million CNY for the years 2025, 2026, and 2027 respectively [1]

Core Viewpoint - The stock of Basilea Pharmaceutica (02616) surged over 8% towards the end of trading, with a current increase of 6.73%, reaching HKD 6.66, and a trading volume of HKD 93.123 million, following the approval of a new indication for Sugli monoclonal antibody by the UK MHRA for treating specific adult patients with non-small cell lung cancer (NSCLC) [1] Company Developments - Basilea Pharmaceutica announced that the UK MHRA has approved the new indication for Sugli monoclonal antibody, which is to be used as a monotherapy for adult patients with unresectable stage III NSCLC who have PD-L1 expression ≥1%, no EGFR sensitive mutations, or ALK/ROS1 genomic alterations, and have not shown disease progression after platinum-based chemoradiotherapy [1] - According to a report from Ping An Securities, Basilea Pharmaceutica is leveraging clinical development as a driving force, with its R&D 1.0 phase commercial products contributing reliable cash flow, while the R&D 2.0 phase focuses on innovative project layouts and cutting-edge technologies [1] Financial Projections - The core products of Basilea Pharmaceutica have entered clinical trial stages, and the company is expected to continue advancing candidate projects into clinical trials [1] - Revenue projections for Basilea Pharmaceutica are estimated to reach HKD 195 million, HKD 464 million, and HKD 633 million for the years 2025, 2026, and 2027, respectively, with the initial coverage rating set at "Recommended" [1]

Group 1 - The core stock of the company, 基石药业, has seen a price increase of over 6%, with a cumulative rise of more than 25% in the month [1] - As of the report, the stock is trading at 6.68 HKD with a transaction volume of 1.02 million HKD [1] - On February 23, 基石药业 announced that its PD-L1 antibody,舒格利单抗, has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for a new indication in the treatment of non-small cell lung cancer (NSCLC) [1] - This approval follows the European Commission's (EC) authorization obtained in July 2024, marking a significant breakthrough in the European core market [1] Group 2 - The company's core asset, CS2009, a tri-specific antibody targeting PD-1/VEGF/CTLA-4, has recently received FDA approval for its Phase II clinical trial IND application for advanced solid tumors [1] - This approval signifies an important advancement in the global development of this innovative immunotherapy [1]

Core Viewpoint - The stock of Basilea Pharmaceutica (02616) has increased over 6%, with a cumulative rise of over 25% in the month, reflecting positive market sentiment following recent regulatory approvals [1] Group 1: Regulatory Approvals - Basilea Pharmaceutica announced that its PD-L1 antibody, Sugli monoclonal antibody, has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for a new indication in Phase III non-small cell lung cancer (NSCLC) [1] - This approval follows the European Commission (EC) license obtained in July 2024, marking a significant breakthrough in the European core market [1] Group 2: Clinical Trials - Basilea's core asset, CS2009, has received FDA approval for its Investigational New Drug (IND) application for a Phase II clinical trial targeting advanced solid tumors [1] - CS2009 is a tri-specific antibody targeting PD-1/VEGF/CTLA-4, indicating important progress in the global development of this innovative immunotherapy [1]

Core Viewpoint - 基石药业-B's stock rose over 5% following the approval of a new indication for Shugli monoclonal antibody by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for treating adult patients with inoperable stage III small cell lung cancer (NSCLC) [1] Group 1: Company Developments - 基石药业-B's stock increased by 5.12%, reaching HKD 6.36, with a trading volume of HKD 23.93 million [1] - The MHRA approved Shugli monoclonal antibody for use as a monotherapy in adult patients with NSCLC who have PD-L1 expression ≥1%, no EGFR sensitive mutations or ALK/ROS1 genomic alterations, and have not shown disease progression after platinum-based chemoradiotherapy [1] - This approval marks the second indication for Shugli monoclonal antibody in the UK, following a previous approval from the European Commission [1] Group 2: Market Expansion - Shugli monoclonal antibody has secured four commercialization partnerships across Europe, the Middle East, Africa, and Latin America, covering over sixty countries and regions [1] - The company is actively advancing its commercialization efforts in international markets [1]

Core Viewpoint - 基石药业-B's stock rose over 5% following the approval of a new indication for Shugli monoclonal antibody by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for treating specific adult patients with inoperable stage III non-small cell lung cancer (NSCLC) [1] Group 1 - 基石药业-B's stock increased by 5.12%, reaching HKD 6.36, with a trading volume of HKD 23.93 million [1] - The MHRA approved Shugli monoclonal antibody for use in adult patients with NSCLC who have PD-L1 expression ≥1%, no EGFR sensitive mutations or ALK/ROS1 genomic alterations, and have not shown disease progression after platinum-based chemoradiotherapy [1] - This approval follows the European Commission's approval, marking the second indication approval for Shugli monoclonal antibody in the UK [1] Group 2 - Shugli monoclonal antibody has established four commercialization partnerships across Europe, the Middle East, Africa, and Latin America, covering over 60 countries and regions [1] - The company is actively advancing its commercialization efforts overseas [1]

Important Events - BGI Genomics plans to sell 100% equity of Complete Genomics for $50 million and adjust the licensing of CoolMPS sequencing technology [1] - Base Pharmaceuticals received approval from the UK MHRA for Sugli monoclonal antibody's new indication in non-small cell lung cancer [1] - Frontline Bio signed a licensing agreement with GlaxoSmithKline, receiving an upfront payment of $40 million and potential milestone payments totaling up to $950 million (approximately 6.56 billion RMB) [1] - Bai Li Tian Heng's clinical trial for iza-bren (EGFR×HER3 dual antibody ADC) in locally advanced or metastatic triple-negative breast cancer reached its primary endpoint in interim analysis [1] - Huagong Technology's AI high-speed optical module orders are scheduled to run through the fourth quarter, with production bases in Wuhan and Thailand fully operational [1] - Wuliangye has distributed over 76.8 billion RMB in dividends over the past five years [1] - Tongfu Microelectronics' application for a specific stock issuance has been accepted by the Shenzhen Stock Exchange [1] Bids - Donghong Co., Ltd. won a procurement project for pressure steel pipes and accessories worth 353 million RMB [1] - Jintanglan's subsidiary won a project for the Sabah Intercontinental Resort Hotel in Malaysia, amounting to approximately 281 million RMB [1] - Shuangliang Energy's wholly-owned subsidiary won a bid for the cooling island system of an H-class combined cycle power plant project in the Middle East, with a bid amount of 100.26 million RMB [1] Performance - Jiantao Group expects a more than 165% increase in net profit for 2025 compared to the same period in 2024 [1] Buybacks & Increases - Luxshare Precision conducted its first share buyback, repurchasing 9.9 million shares for nearly 500 million RMB [2] - Tongce Medical's chairman and others plan to increase their holdings in the company by 6 to 12 million RMB [2]

Group 1 - Heptares Therapeutics has entered into a licensing and equity cooperation agreement with Solstice Oncology for HBM4003, granting exclusive rights for development and commercialization outside Greater China, with potential upfront payments exceeding $105 million [1] - Frontier Biotech has signed an exclusive licensing agreement with GlaxoSmithKline (GSK) for two small RNA (siRNA) pipeline products, one of which is in the IND stage, marking a significant breakthrough in its international strategy [2] - CStone Pharmaceuticals has received approval from the UK Medicines and Healthcare products Regulatory Agency for a new indication of Sugli monoclonal antibody for treating adult patients with advanced non-small cell lung cancer, highlighting its global operational capabilities [3] Group 2 - Novo Nordisk's stock has dropped significantly following the disappointing clinical data for CagriSema, which showed only a 23% weight loss effect, failing to meet the primary endpoint of the trial [4] - Tongce Medical's chairman and executives have announced plans to increase their shareholding in the company, aiming to stabilize market sentiment amid pressures from weak consumer demand and dental implant procurement [5]